Oligonucleotide Pool Market

Increasing focus on new oligonucleotide therapies is driving the market growth

Market CAGR for the oligonucleotide pool is being driven by the increasing focus on new oligonucleotide therapies. Pharmaceutical and biotechnological companies are focusing on the R&D of new oligonucleotide drugs due to the presence of a limited number of approved drugs. Oligonucleotides efficiently target disease-relevant proteins and genes inaccessible by small-molecule drugs and biological drugs. Recent advances have helped overcome challenges associated with the administration, cellular uptake, biodistribution, and side effects of oligonucleotide therapies. Many oligonucleotide therapeutics are in various clinical trials to treat many diseases, including viral infections, rare genetic disorders, neural and neuromuscular conditions, and cancers.

The presence of these drugs and an increase in R&D are expected to drive the oligonucleotide pool market revenue.

The increasing prevalence of chronic and life-threatening diseases has also prompted pharmaceutical companies and research firms to focus on R&D activities to develop effective therapeutics. As a result, life science research advances are leading to an improved understanding of biological systems. Developing oligonucleotide synthesis technologies has helped pharmaceutical and biotechnology researchers with molecular-level development, design, and modification of biological systems. The increasing research activities in the pharmaceutical and biotechnology sectors will expand the  market.

The emergence of oligonucleotide-based therapies increases the demand for oligonucleotide pool libraries. Oligonucleotides are poly nucleic acids made up of five base pairs called oligos. They work by changing the gene expression of the person they impact. Developing oligonucleotide-based therapies is evolving for various diseases, including respiratory diseases, cancer,influenza, and STDs. Currently, only two oligonucleotide therapeutics are approved by the FDA, namely the antisense oligonucleotide Fomivirsen and the aptamer Macugen. The FDA has authorized several antisense medicines, the majority of which are used to treat rare illnesses such as Batten disease, CMV retinitis, Duchenne muscular dystrophy, and spinal muscular atrophy.

Initiatives taken by key players and government support are also playing a crucial role in the oligonucleotide pool library market growth. Many industry players are working on various strategies for emerging technologies for oligonucleotide pool libraries. The government also supports developing novel therapies based on genes for rare diseases. For instance, in August 2021, The News Agency of Nigeria (NAN) reported that Federal Government is expected to increase research and healthcare development investments to boost the health sector. Under this investment ministry of state, health is expected to inaugurate an oligo-synthesis laboratory.

The Global Oligonucleotide Pool Market Industry is projected to experience substantial growth over the coming years. With an estimated market value of 1.67 USD Billion in 2024, the industry is expected to reach 4.03 USD Billion by 2035. This growth trajectory reflects a compound annual growth rate of 8.33% from 2025 to 2035. The increasing demand for oligonucleotide-based therapies and diagnostics, coupled with advancements in synthesis technologies, underpins this optimistic outlook. As the market evolves, it is likely to attract further investments and innovations, solidifying its position as a critical component of modern biomedical research and therapeutic development.

The Global Oligonucleotide Pool Market Industry is witnessing a rise in applications within the diagnostics sector, particularly in molecular diagnostics and infectious disease testing. Oligonucleotides serve as essential components in various diagnostic assays, enabling the detection of pathogens and genetic mutations. The increasing prevalence of chronic diseases and the need for rapid diagnostic solutions are driving this trend. As healthcare systems globally prioritize early detection and personalized treatment, the demand for oligonucleotide-based diagnostic tools is likely to expand. This growth in diagnostics not only enhances patient care but also contributes to the overall market expansion, indicating a robust future for oligonucleotide applications.

The Global Oligonucleotide Pool Market Industry experiences a notable surge in demand for personalized medicine, driven by advancements in genomics and biotechnology. Personalized therapies, which utilize oligonucleotides for targeted treatment, are becoming increasingly prevalent. For instance, the development of oligonucleotide-based therapies for genetic disorders showcases the industry's potential. As the market is projected to reach 1.67 USD Billion in 2024, the emphasis on tailored treatments is likely to propel growth further. This trend indicates a shift towards precision medicine, where oligonucleotides play a crucial role in developing individualized therapies, thereby enhancing patient outcomes.

The Global Oligonucleotide Pool Market Industry benefits from the increasing investment in genomic research, which is pivotal for understanding genetic diseases and developing novel therapies. Governments and private entities are allocating substantial funds to genomic initiatives, fostering innovation in oligonucleotide applications. For example, initiatives aimed at mapping human genomes and understanding genetic variations are driving the demand for oligonucleotide pools. This trend is expected to sustain a compound annual growth rate of 8.33% from 2025 to 2035, reflecting the growing recognition of genomics as a cornerstone of modern medicine and the essential role of oligonucleotides in this field.

The Global Oligonucleotide Pool Market Industry is positively influenced by regulatory support for oligonucleotide therapies, which facilitates their development and approval. Regulatory agencies are increasingly recognizing the therapeutic potential of oligonucleotides, leading to streamlined approval processes for innovative treatments. This supportive regulatory environment encourages investment and research in oligonucleotide-based therapies, fostering market growth. As more therapies receive regulatory endorsement, the market is likely to see an influx of novel products, further driving its expansion. The alignment of regulatory frameworks with scientific advancements in oligonucleotide technology suggests a promising trajectory for the industry.

Technological innovations in oligonucleotide synthesis are significantly influencing the Global Oligonucleotide Pool Market Industry. Enhanced synthesis techniques, such as solid-phase synthesis and automated platforms, improve the efficiency and yield of oligonucleotide production. These advancements not only reduce costs but also enable the rapid development of diverse oligonucleotide libraries for research and therapeutic applications. As a result, the market is expected to grow substantially, with projections indicating an increase to 4.03 USD Billion by 2035. The continuous evolution of synthesis technologies is likely to support the rising demand for high-quality oligonucleotides across various sectors, including pharmaceuticals and diagnostics.

By region, the study provides market insights into North America, Europe, Asia-Pacific and the Rest of the World. The North American oligonucleotide pool market area will dominate this market, owing to the presence of many market players and various developments done by them is the key factor driving the region's growth. Moreover, technological advancements, high investment in R&D, and rising demand for innovative oligonucleotide pools are other factors supporting the regional market. Further, the US oligonucleotide pool market held the largest market share, and the Canadian oligonucleotide pool market was the fastest-growing market in the European region.

Further, the prominent countries studied in the market report are The US, Canada, German, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

Figure 2 Oligonucleotide Pool Market Share By Region 2022 (USD Billion)

Source Secondary Research, Primary Research, MRFR Database and Analyst Review

Europe's oligonucleotide pool market accounts for the second-largest market share owing to the growing number of companies operating in the region adopting various strategies, including research initiatives, product launches, and others, to propel the market growth. Further, the German oligonucleotide pool market held the largest market share, and the UK oligonucleotide pool market was the fastest-growing market in the European region.

The Asia-Pacific oligonucleotide pool market is expected to grow at the fastest CAGR from 2024 to 2032. This is due to the presence of a large population and increasing awareness regarding the oligonucleotide pool. Moreover, China’s oligonucleotide pool market held the largest market share, and the Indian oligonucleotide pool market was the fastest-growing market in the Asia-Pacific region.

Leading market players are investing heavily in research and development to expand their product lines, which will help the oligonucleotide pool market grow even more. Market participants are also undertaking numerous strategic activities to expand their footprint, with important market developments including new product launches, contractual agreements, mergers and acquisitions, higher investments, and collaboration with other organizations. To expand and survive in a more competitive and rising market climate, the oligonucleotide pool industry must offer cost-effective items.

Manufacturing locally to minimize operational costs is one of the key business tactics manufacturers use in the oligonucleotide pool industry to benefit clients and increase the market sector. Major players in the oligonucleotide pool market, including Agilent Technologies, Creative Biogene, CustomArray, Inc., Integrated DNA Technologies, Inc., MYcroarray, Sigma-Aldrich Co. LLC, and others, are attempting to increase market demand by investing in research and development operations.

Pfizer Inc discovers, develops, manufactures, and commercializes biopharmaceuticals. The company offers products to treat cardiovascular, metabolic and pain conditions, women's health, cancer, inflammation, immune disorders, and rare diseases. It also delivers sterile injectable pharmaceuticals, biosimilars, active pharmaceutical ingredients and contract manufacturing services. Pfizer markets its products through wholesalers, retailers, hospitals, individual delivery offices, clinics, government agencies and pharmacies. It has prominent manufacturing facilities in India, China, Japan, Ireland, Italy, Belgium, Germany, Singapore, and the US.

In January 2021, Pfizer Inc., a pharmaceutical and Biotechnology company, announced that it had invested a total of US$ 120 million in 4 clinical-stage biotech firms, as part of the Pfizer Breakthrough Growth Initiative (PBGI), during the second half of the year 2020.

GSK plc (GSK) is a healthcare company focusing on developing, manufacturing and commercializing general medicines, specialty medicines and vaccines. It offers drugs for treating diseases such as HIV, respiratory, cancer, immuno-inflammation, anti-viral, central nervous system (CNS), metabolic, cardiovascular, urogenital, anti-bacterial, dermatology and rare diseases. The company also offers over-the-counter (OTC) products for pain relief, oral health, nutrition, skin health and gastrointestinal diseases. GSK's vaccine portfolio covers various diseases, including hepatitis, tetanus, whooping cough, diphtheria, rotavirus and HPV infections, measles, and bacterial meningitis. The firm sells its products through wholesalers, pharmacies, hospitals, physicians and other groups ly.

In June 2022, GSK plc announced an approximately US$ 1.08 million investment over ten years to accelerate research and development (R&D) activities for infectious diseases that disproportionately impact lower-income countries.